Literature DB >> 22175093

Schedules of controlled substances: placement of ezogabine into Schedule V. Final rule.

.   

Abstract

With the issuance of this final rule, the Administrator of the Drug Enforcement Administration (DEA) places the substance ezogabine, including its salts, isomers, and salts of isomers whenever the existence of such salts, isomers, and salts of isomers is possible, into Schedule V of the Controlled Substances Act (CSA). This action is pursuant to the CSA which requires that such actions be made on the record after opportunity for a hearing through formal rulemaking.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 22175093

Source DB:  PubMed          Journal:  Fed Regist        ISSN: 0097-6326


  6 in total

1.  Carisoprodol pharmacokinetics and distribution in the nucleus accumbens correlates with behavioral effects in rats independent from its metabolism to meprobamate.

Authors:  Theresa M Carbonaro; Vien Nguyen; Michael J Forster; Michael B Gatch; Laszlo Prokai
Journal:  Neuropharmacology       Date:  2020-05-29       Impact factor: 5.250

2.  Activation of KCNQ Channels Prevents Paclitaxel-Induced Peripheral Neuropathy and Associated Neuropathic Pain.

Authors:  Lin Li; Jinxiu Li; Yan Zuo; Danny Dang; Jeffrey A Frost; Qing Yang
Journal:  J Pain       Date:  2018-11-22       Impact factor: 5.820

Review 3.  The Pharmacology and Toxicology of Third-Generation Anticonvulsant Drugs.

Authors:  Paul LaPenna; Laura M Tormoehlen
Journal:  J Med Toxicol       Date:  2017-08-16

Review 4.  New antiepileptic medication linked to blue discoloration of the skin and eyes.

Authors:  Sarah Clark; Alexandra Antell; Kimberly Kaufman
Journal:  Ther Adv Drug Saf       Date:  2015-02

5.  Assessing the Value of the Zebrafish Conditioned Place Preference Model for Predicting Human Abuse Potential.

Authors:  A J Brock; S M G Goody; A N Mead; A Sudwarts; M O Parker; C H Brennan
Journal:  J Pharmacol Exp Ther       Date:  2017-08-08       Impact factor: 4.030

6.  Synthetic cathinone abuse.

Authors:  Michael Capriola
Journal:  Clin Pharmacol       Date:  2013-07-02
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.